Mylan sued for patent infringement over Aubagio

Sanofi and Genzyme have filed a complaint against Mylan for patent infringement over the drug Aubagio (teriflunomide), a treatment for relapsing forms of multiple sclerosis.

The case, which was filed on Tuesday, January 10 in the US District Court for the District of Delaware, arose after Mylan filed an Abbreviated New Drug Application with the Food and Drug Administration seeking approval to market a generic version of the drug.

Patents involved in the lawsuit are US numbers 6,794,410; 8,802,735; and 9,186,346.

Sanofi and Genzyme have asked the court for a judgment which declares that the patents have been infringed.

The companies have also asked the court to enjoin Mylan from bringing the generic drug to market, as well as be awarded damages.